A new study published in the *Journal of the American Heart association* reveals individuals with systemic autoimmune inflammatory diseases (SAIDs) face a substantially elevated risk of heart failure, even when accounting for customary heart disease risk factors[[1]]. Researchers analyzed data from nearly 183,000 adults across Belgium adn Canada, finding substantially increased risk especially among those with scleroderma, systemic lupus erythematosus (SLE), and rheumatoid arthritis.The findings highlight a critical, and often overlooked, connection between autoimmune conditions and cardiovascular health as the prevalence of these diseases continues to rise globally.
Individuals living with systemic autoimmune inflammatory diseases (SAIDs) face a significantly increased risk of developing heart failure, even when traditional cardiovascular risk factors are accounted for, a recent study reveals.
The large, retrospective cohort study, published recently in the Journal of the American Heart Association, highlights a previously underappreciated connection between autoimmune conditions and cardiac health. Understanding these links is crucial as autoimmune diseases become increasingly prevalent.
Researchers from Belgium and Canada analyzed electronic health records of nearly 183,000 adults diagnosed with various SAIDs, including scleroderma, systemic lupus erythematosus (SLE), rheumatoid arthritis, and psoriatic arthritis.
Compared to a control group without SAIDs, and also when compared to individuals with inflammatory bowel disease, those with scleroderma exhibited a 2.81-fold increased risk of heart failure. The risk was elevated by 64% for individuals with SLE (HR 1.64) and 54% for those with rheumatoid arthritis (HR 1.54).
Notably, the increased risk appeared largely independent of established cardiovascular risk factors, suggesting that the autoimmune processes themselves play a direct role in cardiac complications, researchers said. This finding points to the need for a more nuanced understanding of heart disease risk in these patient populations.
The study also indicated a potential benefit associated with beta-blocker use. Researchers found that baseline use of beta-blockers was linked to a 30% reduction in the incidence of heart failure among individuals with scleroderma, SLE, and rheumatoid arthritis combined.
These findings underscore the importance of cardiovascular monitoring for patients with SAIDs and raise the possibility that beta-blockers could have a preventative role. Further prospective research is needed to confirm this potential benefit, according to the study.
Source:
